Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease
worldwide. With no Food and Drug Administration approved drugs, current treatment options …

Chronic diseases represent a major challenge in world health. Metabolic syndrome is a
constellation of disturbances affecting several organs, and it has been proposed to be a liver …

Excessive sugar consumption and defective glucose sensing by hepatocytes contribute to
the development of metabolic diseases including type 2 diabetes mellitus (T2DM) and …

Objective Recent studies suggest that excess dietary fructose contributes to metabolic
dysfunction by promoting insulin resistance, de novo lipogenesis (DNL), and hepatic …

Non-alcoholic fatty liver disease (NAFLD) is a liver manifestation of metabolic syndrome,
and is estimated to affect one billion individuals worldwide. An increased intake of a high-fat …

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly defined as non-
alcoholic fatty liver disease (NAFLD), is a disorder marked by the excessive deposition of …

Background & Aims The consumption of sugar and a high-fat diet (HFD) promotes the
development of obesity and metabolic dysfunction. Despite their well-known synergy, the …

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
worldwide, with an estimated prevalence of 25% in the Western World. NAFLD is a broad …

Elevations in fructose consumption have been reported to contribute significantly to an
increased incidence of obesity and metabolic diseases in industrial countries …

While the uses of retinoids for cancer treatment continue to evolve, this review focuses on
other therapeutic areas in which retinoids [retinol (vitamin A), all-trans retinoic acid (RA), and …